TNF-related apoptosis-inducing ligand (TRAIL, also known as Apo-2L) represents a novel promising anticancer agent whose activity is solely dependent on its ability to induce apoptosis in tumour cells (Ferreira et al, 2002; MacFarlane, 2003). Here, TNFSF10 is linked to neoplasm.